Progenics Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PGNX)

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Friday, August, 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The biotechnology company had revenue of $9.97 million for the quarter, compared to the consensus estimate of $6.40 million. Progenics Pharmaceuticals had a negative return on equity of 65.17% and a negative net margin of 339.86%. View Progenics Pharmaceuticals' Earnings History.

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Progenics Pharmaceuticals.

4 analysts have issued 1-year target prices for Progenics Pharmaceuticals' shares. Their forecasts range from $6.50 to $14.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $10.17 in the next twelve months. This suggests a possible upside of 96.3% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.

News stories about PGNX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a news impact score of -2.6 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Progenics Pharmaceuticals.

Progenics Pharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 10,410,000 shares, a drop of 5.5% from the August 30th total of 11,020,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the short-interest ratio is currently 8.6 days. Currently, 13.4% of the shares of the stock are short sold. View Progenics Pharmaceuticals' Current Options Chain.

Some companies that are related to Progenics Pharmaceuticals include Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Apellis Pharmaceuticals (APLS), Pacira Biosciences (PCRX), Aimmune Therapeutics (AIMT), Tricida (TCDA), Insmed (INSM), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL) and Nabriva Therapeutics (NBRV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Vonage (VG), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Portola Pharmaceuticals (PTLA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and Opko Health (OPK).

Progenics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View Institutional Ownership Trends for Progenics Pharmaceuticals.

PGNX stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc and Velan Capital, LP. View Insider Buying and Selling for Progenics Pharmaceuticals.

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PGNX stock can currently be purchased for approximately $5.18.

Progenics Pharmaceuticals has a market capitalization of $448.69 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.View Additional Information About Progenics Pharmaceuticals.

The official website for Progenics Pharmaceuticals is http://www.progenics.com/.

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]